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Purpose. Choroidal neovascularization (CNV) is one of the most common complications of retinal diseases accompanied by
elevated secretion of vascular endothelial growth factor (VEGF). Intravitreal anti-VEGFs (ranibizumab, bevacizumab, pegaptanib,
and aflibercept) can suppress neovascularization, decrease vascular permeability and CNV size, and, thereby, improve visual
function. The antiproliferative, apoptotic, and autophagic effect of anti-VEGF drugs on fibroblasts found in CNVs has not been
yet explored.Methods. Concentration-dependent cellular effects of the four anti-VEGFs were examined in L929 fibroblasts over a
5-day period. The cell survival, mitotic and polykaryocytic indices, the level of apoptosis and autophagy, and the cellular growth
kinetics were all assessed. Results. The anti-VEGFs could inhibit the survival, mitotic activity, and proliferation as well as increase
the cellular heterogeneity, apoptosis, and autophagy of the fibroblasts in a dose-dependent manner. Cellular growth kinetics
showed ranibizumab to be less aggressive, but three other anti-VEGFs showed higher antiproliferative and apoptotic activity and
expressed negative cellular growth kinetics. Conclusions. The antiproliferative, apoptotic, and autophagic activity of anti-VEGFs
upon fibroblasts may explain the cellular response and the etiology of CNV involution in vivo and serve as a good study model for
CNV in vitro.
1. Introduction
The development of choroidal neovascularization (CNV) is
one of the most sight threatening complications of different
retinal diseases such as age-related macular degeneration,
pathologic myopia, angioid streaks, and choroidal rupture.
Foveal or extrafoveal location of CNV limits the use of lasers
due to its potential side effects on the surrounding healthy
tissue. The effectiveness of intravitreal administration of dif-
ferent antivascular endothelial growth factors (anti-VEGFs)
is well known in the treatment of CNV of different origin [1–
4]. The mechanism how intravitreal injections (IVIs) of such
drugs work is complex and involves blocking of various
types of VEGFs, decreased permeability of newly formed
blood vessel walls, and reduced swelling of the retinal
layers. Our optical coherence tomography (OCT) and flu-
orescein angiography (FA) performed before and after IVI
of anti-VEGF drugs have revealed significant involution and
decrease of CNV size (Figure 1).
The exact mechanism which leads to decrease of the
CNVdimensions is notwell understood.During recent years,
a number of studies have published the impact of anti-VEGF
drugs upon different cellular cultures in vitro [5–10]. Fibrob-
lasts and myofibroblasts being among the most common
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Figure 1: Choroidal neovascularization (CNV) dynamics after repeated anti-VEGF therapy (CNV size is circumscribed with yellow color;
images shown are at the 40th second of fluorescein angiography).
cells found within the cellular matrix of CNVs and known
to have high mitotic activity [7] have not been examined for
their cellular effects upon anti-VEGF drug treatment. Our
goal was to investigate the antiproliferative, apoptotic, and
autophagic effects of anti-VEGF drugs on a fibroblast-like
cell strain which can serve as in vitro model for CNV cel-
lular matrix formation and to analyze the dose dependence
regarding antiproliferative activity.
2. Materials and Methods
2.1. Cell Culture and Treatment Regimes. In vitro studies were
performed using a fibroblast-like mouse cell strain L929
obtained from ATCC and cultivated according to conven-
tional methods [11, 12] and nutrient medium composed of
RPMI-1640 supplemented with fetal calf serum (10%) and
gentamicin (10mg/mL). Cultivation of the cell strain with
different concentration of anti-VEGF drugs was performed as
described below.
Ranibizumab (Lucentis, Novartis, Switzerland), a frag-
ment of a human monoclonal antibody against VEGF-A,
which is secreted by recombinant strain of Escherichia coli
and its isoforms selectively bind to VEGF-A (VEGF
110
,
VEGF
121
, and VEGF
165
), was added to the culture 24 hours
after fresh cell plating in concentrations of 12.5, 50, 125, and
250𝜇g/mL.
Bevacizumab (Avastin, Genetech/Roche, USA), a mon-
oclonal antibody against VEGF, which is used off-label to
treat various eye diseases in which increased concentration of
VEGF is found and neovascularization is present, was added
to the culture 24 hours after fresh cell plating at concentra-
tions of 0.65, 3.13, 6.5, and 12.5𝜇g/mL.
Pegaptanib (Macugen, Pfizer, USA), a pegylatedmodified
oligonucleotide that binds selectively andwith high affinity to
an extracellular VEGF
165
, was added to the culture 24 hours
after fresh cell plating at concentrations of 0.075, 0.15, 0.3,
0.75, and 1.5 𝜇g/mL.
Aflibercept (Eylea, Bayer HealthCare, Germany), a fusion
protein approved in the United States and Europe for the
treatment of wet form of age-related macular degeneration,
working by binding to circulating VEGF (subtypes VEGF-A
and VEGF-B), as well as to placental growth factor (PGF),
thus inhibiting growth of new blood vessels in the choriocap-
illaris [2], was added to the culture 24 hours after cell plating
at concentrations of 0.04, 0.08, 0.2, 0.4, and 0.5 𝜇g/mL.
Minimal drug concentrations were established according
to the appearance of a multiplex of cellular effects (cellu-
lar proliferation, mitotic activity, polykaryocytic index, and
apoptosis) and applied into the study, while maximal concen-
trations were determined with relevance and close approxi-
mation to the ones used in clinical practice (e.g., 0.5mg/4mL
vitreous volume for ranibizumab; 1.25mg/4mL vitreous
volume for bevacizumab; 0.3mg/4mL vitreous volume for
pegaptanib; 2.0mg/4mL vitreous volume for aflibercept; all
of the anti-VEGFs are used clinically at 1–3-month interval).
2.2. Cellular Vital Parameters. Different cellular responses
were evaluated on a daily basis up to 5 days. The following
cellular vital activity indices were evaluated: cellular growth/
expansion and mitotic and polykaryocytic indices (PKI). For
cultivation, 5 × 104 cells were added to the cell culture dishes
covered by culture glass slides (size 16 × 8mm) and filled up
to 1mL of medium and then left to form monolayers within
5 days. Anti-VEGFs were added to the cultures 24 hours after
cell plating in different concentrations specified accordingly.
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Figure 2: Kinetics of the cellular survival (a) and mitotic (b) and polykaryocytic indices (c) in untreated, control L929 cells.
The samples were fixed for analysis in 96% ethanol and then
stained by hematoxylin and eosin (H&E). The total number
of cells and the count of mitoses and polykaryocytes (2
or more nuclei) were determined under optical microscope
(Axioscope, Germany) at 1000x magnification within a grid
area of 0.05mm2. Mitotic index and PKI were adjusted to
1000 cells (‰). Parallely, cellular vital indices were evaluated
within the intact cellular culture.
2.3. Detection of Apoptosis and Autophagy. The level of
apoptosis was determined on the same cultures in which
the cellular vital indices were analyzed. The cells were
first washed in phosphate buffered saline (PBS) and then
detached for 10 minutes in trypsin and suspended again
in PBS. Consequently, centrifugation (1400 rpm, 5min) and
resuspension of the cells in propidium iodide (1 𝜇g/mL) were
performed. The level of apoptosis was determined according
to the number of apoptotic cells in pre-G1 phase using ductal
cytofluorimeter FACStar Plus (Becton Dickinson, USA).
Anti-LC3 polyclonal antibodywas purchased fromNovus
Biologicals, USA (NB100-2220-0.1) for analysis of autophagy.
Cell lysates were prepared from each condition after which
equal amounts of protein were loaded onto the gel. Proteins
were separated on aNuPAGE 15%Bis-Tris polyacrylamide gel
and then transferred onto Immobilon-P Transfer Membrane
(Millipore, IPVH00010). Membranes were blocked in Tris
buffered saline containing 0.05% Tween-20 (TBS-T) and 5%
nonfat dry milk (BioRad, 170-6435, 170-6531, and 100-04504-
MSDS) for 1 hour. After blocking, membranes were probed
overnight at 4∘Cwith the anti-LC3 antibody in dilution buffer
(TBS-T containing 1% nonfat dry milk), followed by 1-hour
incubation with a peroxidase-conjugated rat anti-rabbit sec-
ondary antibody (Sigma, A6154) for 1 hour at room tempera-
ture. Peroxidase activity was detected with SuperSignal West
Femto Maximum Sensitivity Chemiluminescent Substrate
(Pierce, 34095) using a Lumi-Imager (Roche Diagnostics,
Mannheim, Germany).
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Figure 3: Cellular effects of ranibizumab (a), bevacizumab (b), pegaptanib (c), and aflibercept (d) on L929 cells. Cells shown are at Day 5 of
various treatment concentrations (H&E staining, magnification ×1000).
2.4. Cellular Growth Kinetics. Proliferative activity of cells
was determined according to their growth kinetics parame-
ters: specific growth velocity (𝜇), population doubling time
(𝑡
𝑑
), and reproduction velocity (𝑛) at Day 5 of the observation
[13]. The specific growth velocity of the culture in phase of
logarithmic growth was calculated using the formula 𝜇 =
(ln𝑋 − ln𝑋
𝑜
)𝑡
−1, where 𝑋 is the cell quantity after certain
time interval 𝑡 (Day 5 of cultivation), 𝑋
𝑜
is the cell quantity
onDay 1 of cultivation, and 𝑡 is the time of observation (5 days
of cultivation). Using specific growth velocity, population
doubling time was calculated as 𝑡
𝑑
= ln 2/𝜇 = 0693𝜇. Repro-
duction velocity (𝑛) was determined using the formula 𝑛 =
3.32 log(𝑋/𝑋
𝑜
).
2.5. Statistical Analysis. Results were statistically analyzed by
Student’s 𝑡-test using Microsoft Excel and Biostat (Primer of
Biostatistics, Version 4.03, by Stanton A. Glantz). 𝑃 < 0.05
was considered significant. If not otherwise noted, all the
experiments were performed three times independently.
3. Results
3.1.Morphological and Functional Characteristics of L929Cells
Treated by Anti-VEGFs. Under normal conditions, L929 cells
form a dense cellular monolayer with the majority of the cells
acquiring polygonal and spindle shape morphology.The cells
have relatively large nuclei, light cytoplasmic vacuoles, and
small granules with occasional di- and trinucleated cells
found in the culture. On average, 2 to 5 cells at different stages
of mitosis can be detected per visual field in the untreated
culture, assuming round shape, small cytoplasm, and hyper-
chromatic nuclei due to condensation of the chromatin under
mitosis. The intact cells have a characteristic proliferative
activity that increases fromDay 1 toDay 5 of cultivation (loga-
rithmic growth phase), reaching growth plateau at Day 6 (sta-
tionary growth phase), when the density of the cellularmono-
layer becomes highest (58.0 ± 2.7/0.05mm2) (Figure 2(a)).
Maximummitotic activity is observed at Day 3 of cultivation
(166.0 ± 7.5‰), with a decrease in the mitotic index at Day 4
due to contact inhibition and confluency of the cellular
culture. The PKI in the intact control cells varies between 8
and 12‰.
Incubation of the L929 cells with ranibizumab at a con-
centration of 12.5 𝜇g/mL leads to decreased density of the
culture monolayer by 3 times (Figures 3(a) and 4(a)), which
is caused by the appearance of increased number of cells with
apoptotic features—decreased cytoplasm and condensed
chromatin in the nucleus (Figures 3(a) (red arrow) and 4(d)).
The treated cells assume mainly spindle-shape morphology,
while their PKI increases by 54‰ (Figure 4(c)), a sign of cell
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Figure 4: Kinetics of cellular proliferation (a), mitotic activity (b), polykaryocytic index (c), and apoptosis (d) in L929 cells treated by
ranibizumab at different concentrations (data shown are at Day 5 of the treatment; 𝑛 = 3, ∗𝑃 < 0.05).
demise. At higher concentrations up to 125.0𝜇g/mL, the het-
erogeneity of the cell culture increases, with a predominant
cellular morphology being round and polygonal (Figure 3(a)
(yellow arrow)). The number of polykaryocytes markedly
increases to 62‰, while the mitotic index remains relatively
stable compared to the control (Figure 4(b)). Incubation of
the L929 cells at a dose of 250𝜇g/mL results in severe degra-
dation of the cellular structure and strong vacuolization of the
cytoplasm.
Exposure to bevacizumab at concentration of 0.65 𝜇g/mL
induces no morphological changes in the L929 cells com-
pared to the control (Figure 3(b)). Increasing the dose up
to 3.13 𝜇g/mL leads to an increase in the heterogeneity of
cellular culture, with round and polygonal cellular morphol-
ogy becoming more prominent (Figure 3(b) (red arrow)).
A small number of mitotic cells with vacuolar cytoplasm
can be observed compared to the control, while the number
of polykaryocytes increases 6.3 times (Figure 5(c)), and the
mitotic index and cell number decrease by 1.9 and 1.6 times,
respectively, compared to the control (Figures 5(a) and
5(b)). At higher concentrations of bevacizumab (6.25 and
12.5 𝜇g/mL), a severe degradation of cellular structure, with
the cytoplasm becoming full of vacuoles, and a large number
of apoptotic cells appear (38.0 ± 1.5 and 46.0 ± 2.2, resp.) (Fig-
ures 3(b) (yellow arrow) and 4(d)). A significant reduction
in the cell density and mitotic activity as well as increase in
the PKI is noticed at concentrations higher than 0.625𝜇g/mL
(𝑃 < 0.05) (Figure 5(c)).
Incubation of cells with pegaptanib shows pronounced
antiproliferative effects of the drug from its lowest dose
(0.075𝜇g/mL) (Figure 6(a)) and an almost doubling of the
apoptotic cells in the culture. This is manifested by a sig-
nificant decrease in the cell number and mitotic activity
compared to the controls (𝑃 < 0.05) (Figures 6(a) and 6(b)).
Increasing the dose up to 1.5 𝜇g/mL increases the antipro-
liferative effect which is manifested through a reduction in
the density of the cells and the appearance of vacuoles in the
cytoplasm (Figure 3(c) (red arrow)). Cells with signs of apop-
tosis also appear at higher concentrations (Figure 3(c) (yellow
arrow)), but their number, paradoxically, is similar to that of
the control cells (Figure 6(d)), while the number of mitoses
and presence of polykaryocytes decreases and increases,
respectively (Figures 6(b) and 6(c)).
Exposure to aflibercept causes not much morphological
difference in the L929 cells compared to the control; for exam-
ple, the cells remain predominantly polygonal and spindle
shaped with centrally situated well-colored round or oval
nuclei (Figure 3(d) (red arrow)). The cytoplasm has mesh
structure and becomes slightly vacuolized under aflibercept
treatment (Figure 3(d) (yellow arrow)), with many cells
6 Journal of Ophthalmology
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Figure 5: Kinetics of cellular proliferation (a), mitotic activity (b), polykaryocytic index (c), and apoptosis (d) in L929 cells treated by
bevacizumab at different concentrations (data shown are at Day 5 of the treatment; 𝑛 = 3, ∗𝑃 < 0.05).
appearing at different stages of mitosis and, under certain
concentrations, an entire absence of polykaryocytes’ forma-
tion is seen compared to control (Figure 7(c)). The cell num-
ber is reduced by at least 1.6-fold with drug concentration
of 10 𝜇g/mL and by 2.2-fold when exposed to a maximum
concentration of 200𝜇g/mL (Figure 7(a)). Interestingly, the
mitotic index does not change compared to the control,
which corresponds well to the morphological cellular sta-
bility observed (Figure 7(b)). Furthermore, complete lack of
polykaryocytes is observed under certain concentrations (10
and 100 𝜇g/mL) (Figure 7(c)).There is no statistical difference
between PKI of control cells and under 50 or 200 𝜇g/mL
treatment with aflibercept (𝑃 < 0.05). The number of apop-
totic cells (Figure 7(d)) increases and depends in a nonlinear
manner on the drug concentration.
3.2. Cellular Growth Kinetics of L929 Cells under Different
Treatments. Comparison of the cellular growth effect of
different concentrations of anti-VEGF drugs is shown in
Figure 8. According to the cellular growth kinetic parameters
(specific growth velocity (𝜇), population doubling time (𝑡
𝑑
),
and cell reproduction velocity (𝑛)), ranibizumab seems to be
less aggressive compared to the rest of the anti-VEGFs stud-
ied, the cellular death being compensated by cellular repro-
duction in its case (Figure 8(a)) [13]. Minimal concentrations
of bevacizumab cause faster cellular proliferation than death
(Figure 8(b)); however, this turns around under higher con-
centrations, when generalized cell death through initiation
of apoptosis occurs. The action of pegaptanib appears to be
antiproliferative at lowest concentrations, while the balance
between survival, reproductive activity, and death is shifted
towards death at higher concentrations, meaning that the
destruction in cellular culture runs faster than cellularmitosis
(Figure 8(c)). Treatment by aflibercept (Figure 8(d)) causes
statistically significant reduction in the cell number, in par-
ticular, concentrations of 50 to 200 𝜇g/mL, while, at the same
time, the population doubling time decreases (at 50 𝜇g/mL),
and the rate of cell proliferation increases. This indicates
a shift of the balance of cellular growth and death in the
culture towards death, and, according to the determination of
number of apoptotic cells (Figure 8(d)), this death is mainly
caused by apoptosis. Concentration of 200𝜇g/mL slows down
the progression of cellular growth, which indicates linking of
the reproductive death (pathologic mitosis) to apoptosis.
3.3. Induction of Autophagy by Ranibizumab and Beva-
cizumab in L929 Cells. The appearance of vacuoles in the
cytoplasm of L929 cells under different treatments by ranibi-
zumab and bevacizumab was further examined for the
presence of autophagy. Both treatment modalities induce
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Figure 6: Kinetics of cellular proliferation (a), mitotic activity (b), polykaryocytic index (c), and apoptosis (d) in L929 cells treated by
pegaptanib at different concentrations (data shown are at Day 5 of the treatment; 𝑛 = 3, ∗𝑃 < 0.05).
conversion of the cytoplasmic form of the myosin light chain
kinase 3 (LC3) I into the autophagic vacuoles-bound LC3 II,
with the highest concentrations of each drug inducing highest
conversion of LC3 I to LC3 II (quantification data not shown)
(Figure 9).
4. Discussion
Over the past decade, IVIs of anti-VEGF drugs take the
leading place among the treatmentmodalities used for retinal
diseases with increased production of VEGF [1–4]. However,
only a few studies are dedicated to the side effects these drugs
have on ocular tissues being exposed [5–10]. To our knowl-
edge, this is the first study which compares antiproliferative
action of ranibizumab, bevacizumab, pegaptanib, and afliber-
cept on fibroblast-like cells in vitro to elucidate the different
dose-dependent properties and implications for CNV.
Our data show that all four anti-VEGFs demonstrate
antiproliferative activity on the L929 cells over a 5-day study
period. Starting from the lowest concentrations used, the
heterogeneity of the cellularmonolayer increases as a result of
depression ofmitosis and survival, while the number of apop-
totic cells increases. Increasing the concentrations of each of
the four anti-VEGFs results in exacerbation of the above-
mentioned effects.
The growth kinetic analysis reveals concentration-depen-
dent antiproliferative and apoptotic effects of all anti-VEGFs,
except for ranibizumab, where higher cellular reproduc-
tion occurs with concentration increase, and, therefore, the
concentration-dependent cellular growth is partially com-
pensated by reproduction. The ranibizumab proves, there-
fore, to be less aggressive than other anti-VEGFs in regard to
its antiproliferative activity.
A recent study compared the antiproliferative and cyto-
toxic effects of bevacizumab, pegaptanib, and ranibizumab
on different ocular cells, except fibroblasts [8]. Ranibizumab
reduced the cell proliferation by 44.1%, while bevacizumab
and pegaptanib reduced it by 38.2% and 35.1%, respectively,
when applied to choroidal epithelial cells (CECs), although
the difference was not found to be statistically significant.
A slight antiproliferative effect of bevacizumab and pegap-
tanib was also revealed on adult retinal pigment epithelium
(ARPE19 cell line). Ranibizumab neither had the same effect
on cell proliferation of ARPE19 cells nor did it have cytotoxic-
ity on retinal ganglion cells (RGC5), CECs, and ARPE19 cells.
It could also efficiently block migration, but not proliferation
8 Journal of Ophthalmology
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Figure 7: Kinetics of cellular proliferation (a), mitotic activity (b), polykaryocytic index (c), and apoptosis (d) in L929 cells treated by
aflibercept at different concentrations (data shown are at Day 5 of the treatment; 𝑛 = 3 ∗𝑃 < 0.05).
induced by growth factor combinations, including VEGF in
retinal endothelial cells.
Another study collated the effects of ranibizumab, pegap-
tanib, and bevacizumab on the different stages of angio-
genesis using cultivation of drugs on human umbilical vein
endothelial cells (HUVEC) [5]. According to the results,
apoptosis of HUVEC was markedly increased by ranibi-
zumab and bevacizumab. Clinically used doses of these
drugs, but not pegaptanib, caused significantly reduced cellu-
lar proliferation without causing cytotoxic effects at all con-
centrations used. Finally, incubation of HUVEC with anti-
VEGF drugs caused a decreased expression of the active form
of the VEGF receptor-2, with bevacizumab causing 66% of
control and ranibizumab and pegaptanib causing 86%
decrease compared to the control.
A separate study compared the cytotoxicity and antipro-
liferative activity of aflibercept, bevacizumab, and ranibi-
zumab on different ocular cells (ARPE19, RGC-5, and 661W)
[7] and concluded that aflibercept does not affect cellular
viability or induce apoptosis. Albeit aflibercept had slight
upregulation and downregulation effects on certain VEGF-
related factors, however, those were not significant when
compared to bevacizumab and ranibizumab.
Our experimental study explored the cellular effects of
four different anti-VEGFs on L929 cells as a model of the
fibroblast-based cellular matrix of CNV in vitro. The results
revealed their effect on the proliferative activity (survival,
proliferative and mitotic activity, and apoptosis) and their
hormesis; that is, small doses of the drugs (ranibizumab
12.5 𝜇g/mL, bevacizumab 3.13 𝜇g/mL, pegaptanib 0.15 𝜇g/mL,
and aflibercept 0.04𝜇g/mL) exhibited a pronounced antipro-
liferative effect on the cellular culture, while bevacizumab
in all concentrations increased apoptosis of the L929 cells.
Inhibition of the proliferation and increased heterogeneity
of these cells under anti-VEGF treatment are a sign of
reproductive cellular death.
When cultured with bevacizumab, pegaptanib, and
aflibercept, the L929 cells showed marked dose-dependent
effects which were manifested by an increase in the antipro-
liferative action with increasing dose. Inversely, ranibizumab
caused compensation of the antiproliferative and apoptotic
action by cellular proliferation in spite of increasing drug con-
centration. This compensation can probably be partially due
to autophagy, which is a self-digestive or self-recyclingmech-
anism found in cells.
The reasons why L929 cell strain was chosen in this
study were the absence of background VEGF secretion, as
well as exploring the alternative cellular effects of anti-VEGF
drugs as an in vitro model for CNV. Indeed, the most highly
proliferating cell types amid the cellular types in CNV are
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concentrations (data shown are at Day 5 of the treatment; 𝑛 = 3).
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Figure 9: Induction of autophagy by ranibizumab and bevacizumab
in L929 cells.
fibroblasts and myofibroblasts [14]. L929 cells have also been
used as in vitromodel for vital cell, allowing to judge cellular
effects of different drugs upon vital, highly proliferating cells.
Although the data regarding presence of absence ofVEGF
receptors on the cellular membrane of fibroblast-like cells in
CNV is missing, other studies have shown VEGF receptor
presence on joint fibroblasts extracted fromhumans as well as
expression of VEGF by inflammatory stimulation of fibrob-
last-like cells that infiltrate the joint in a collagen-induced
arthritis [15]. An obvious limitation of this study is the
resemblance of the in vitro findings to clinical conditions, for
example, CNV.
Antiproliferative and apoptotic properties of anti-VEGF
drugs on fibroblast-like cells can explain an alternative,
beneficial mechanism of their action on such cells and
myofibroblasts found in CNV [14]. Inhibition of the cel-
lular survival and mitosis by ranibizumab, bevacizumab,
pegaptanib, and aflibercept in different concentrations has
to be taken into consideration while using them in patients.
Only ranibizumab, amid all anti-VEGFs studied, exhibits the
slightest antiproliferative activity which allows for compen-
sation of apoptosis by increased proliferation. The complete
absence of polykaryocytes revealed after cultivation with
aflibercept at concentrations of 10 and 100 𝜇g/mL may indi-
cate the influence of the drug on the signal transfer from the
membrane to the nucleus.
10 Journal of Ophthalmology
The identified properties of these drugs require further
investigation of their action in vitro and in vivo. Additionally,
further research pertaining to hormesis of anti-VEGFs needs
to be performed to eliminate possible side effects on healthy
retinal tissues.
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